^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Voyager-V1

    i
    Other names: Voyager-V1, VSV-IFNbeta-sodium iodide symporter, VSV IFNbeta NIS, VSV-hIFNbeta-NIS, VSV-IFN-NIS, VSV-IFNβ-NIS, recombinant vesicular stomatitis virus-expressing interferon-beta, vesicular stomatitis virus oncolytic virus, VSV oncolytic virus
    Associations

    News

    Trials
    Company:
    Vyriad
    Drug class:
    IFNβ stimulant
    Related drugs:
    Associations

    News

    Trials
    28d
    Oncolytic virus therapy for osteosarcoma: mechanisms, opportunities, and challenges. (PubMed, Front Immunol)
    This review systematically summarizes the molecular mechanisms underlying OV-mediated antitumor immunity, evaluates current clinical evidence, and highlights future opportunities, such as combination immunotherapy, mesenchymal stem cell (MSC)-based delivery platforms, and AI-driven precision medicine approaches. Our goal is to provide a comprehensive theoretical framework to support the clinical translation and personalized application of OV therapy in osteosarcoma.
    Review • Journal
    |
    CD8 (cluster of differentiation 8) • IFNB1 (Interferon Beta 1)
    |
    Voyager-V1
    4ms
    Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, Vyriad, Inc. | Recruiting --> Active, not recruiting | N=86 --> 33 | Trial completion date: Dec 2025 --> Sep 2025 | Trial primary completion date: Dec 2025 --> Jul 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Voyager-V1
    5ms
    VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, Mayo Clinic | Trial completion date: Jul 2025 --> Jan 2028
    Trial completion date
    |
    Jakafi (ruxolitinib) • Voyager-V1
    7ms
    Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=17, Completed, Mayo Clinic | Active, not recruiting --> Completed
    Trial completion
    |
    sorafenib • Voyager-V1
    10ms
    Phase 2 Trial of Voyager V1 in Combination with Cemiplimab in Cancer Patients (clinicaltrials.gov)
    P2, N=87, Recruiting, Vyriad, Inc. | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF V600
    |
    Libtayo (cemiplimab-rwlc) • Voyager-V1
    1year
    Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination with Checkpoint Inhibitor Therapy in Patients with Select Solid Tumors (clinicaltrials.gov)
    P1/2, N=86, Recruiting, Vyriad, Inc. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • IFNB1 (Interferon Beta 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Voyager-V1
    over1year
    VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, Mayo Clinic | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jun 2024 --> Aug 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    Jakafi (ruxolitinib) • Voyager-V1
    over1year
    Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Mayo Clinic
    New P1 trial
    |
    Yervoy (ipilimumab) • Libtayo (cemiplimab-rwlc) • Voyager-V1
    almost2years
    Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients (clinicaltrials.gov)
    P2, N=87, Recruiting, Vyriad, Inc. | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF V600
    |
    Libtayo (cemiplimab-rwlc) • Voyager-V1
    almost2years
    Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Vyriad, Inc. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • IFNB1 (Interferon Beta 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Voyager-V1
    almost2years
    VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (clinicaltrials.gov)
    P1, N=120, Recruiting, Mayo Clinic | Trial completion date: Dec 2024 --> Apr 2032 | Trial primary completion date: Dec 2024 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Jakafi (ruxolitinib) • cyclophosphamide • Libtayo (cemiplimab-rwlc) • Voyager-V1
    2years
    VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=77 --> 34
    Enrollment closed • Enrollment change • Metastases
    |
    Jakafi (ruxolitinib) • Voyager-V1